Mostrar el registro sencillo del ítem
Extracellular vesicle PD‑L1 dynamics predict durable response to immune‑checkpoint inhibitors and survival in patients with non‑small cell lung cancer
dc.contributor.author | De Miguel Pérez, Diego | |
dc.contributor.author | Serrano Fernández, María José | |
dc.date.accessioned | 2022-06-27T10:37:09Z | |
dc.date.available | 2022-06-27T10:37:09Z | |
dc.date.issued | 2022-06-02 | |
dc.identifier.citation | de Miguel-Perez, D... [et al.]. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res 41, 186 (2022). [https://doi.org/10.1186/s13046-022-02379-1] | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/75680 | |
dc.description.abstract | Background: Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs. Methods: Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively. Results: As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1 expression, the commonly used biomarker, was not predictive neither for durable response nor survival. Conclusion: These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC who would experience durable benefit from ICIs. | es_ES |
dc.description.sponsorship | Center for Thoracic Oncology Icahn School of Medicine at Mount Sinai | es_ES |
dc.description.sponsorship | Borsa Dottorati FSE XXXII ciclo Unime | es_ES |
dc.description.sponsorship | United States Department of Health & Human Services | es_ES |
dc.description.sponsorship | National Institutes of Health (NIH) - USA | es_ES |
dc.description.sponsorship | NIH National Cancer Institute (NCI) P30CA016672 | es_ES |
dc.description.sponsorship | University of Pittsburgh Hillman Cancer Center | es_ES |
dc.description.sponsorship | Hillman Cancer Center's NCI Cancer Center Support Grant (CCSG) P30CA047904 | es_ES |
dc.description.sponsorship | A.S.S.O. (Associazione Siciliana Sostegno Oncologico) Onlus | es_ES |
dc.description.sponsorship | National Cancer Institute-Cancer Center Support Grant (CCSG) P30CA134274 | es_ES |
dc.description.sponsorship | Merck & Company | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BMC | es_ES |
dc.rights | Atribución 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | Extracellular vesicles | es_ES |
dc.subject | PD-L1 | es_ES |
dc.subject | Biomarkers | es_ES |
dc.subject | Immunotherapy | es_ES |
dc.subject | NSCLC | es_ES |
dc.title | Extracellular vesicle PD‑L1 dynamics predict durable response to immune‑checkpoint inhibitors and survival in patients with non‑small cell lung cancer | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.doi | 10.1186/s13046-022-02379-1 | |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |